Item Type | Name |
Concept
|
Bacterial Vaccines
|
Concept
|
Rabies Vaccines
|
Concept
|
Vaccines, Attenuated
|
Concept
|
Vaccines, Synthetic
|
Concept
|
Viral Hepatitis Vaccines
|
Concept
|
Viral Vaccines
|
Concept
|
Vaccines, Inactivated
|
Concept
|
AIDS Vaccines
|
Concept
|
SAIDS Vaccines
|
Concept
|
Cancer Vaccines
|
Concept
|
Anthrax Vaccines
|
Concept
|
Vaccines, Subunit
|
Concept
|
Ebola Vaccines
|
Academic Article
|
Characterization of a single-cycle rabies virus-based vaccine vector.
|
Academic Article
|
Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways.
|
Academic Article
|
Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity.
|
Academic Article
|
Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge.
|
Academic Article
|
Rabies virus as a research tool and viral vaccine vector.
|
Academic Article
|
Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses.
|
Academic Article
|
Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein.
|
Academic Article
|
Rhabdovirus-based vectors with human immunodeficiency virus type 1 (HIV-1) envelopes display HIV-1-like tropism and target human dendritic cells.
|
Academic Article
|
Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines.
|
Academic Article
|
New approaches to the development of live attenuated rabies vaccines.
|
Academic Article
|
HIV-1 vaccines: the search continues.
|
Academic Article
|
Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic.
|
Academic Article
|
New approaches to the prevention and eradication of rabies.
|
Academic Article
|
Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome.
|
Academic Article
|
Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases.
|
Academic Article
|
In vitro growth and stability of recombinant rabies viruses designed for vaccination of wildlife.
|
Academic Article
|
Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque.
|
Academic Article
|
Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach.
|
Academic Article
|
The application of reverse genetics technology in the study of rabies virus (RV) pathogenesis and for the development of novel RV vaccines.
|
Academic Article
|
A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies.
|
Academic Article
|
Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2.
|
Academic Article
|
Overexpression of tumor necrosis factor alpha by a recombinant rabies virus attenuates replication in neurons and prevents lethal infection in mice.
|
Academic Article
|
Immunogenicity of cytopathic and noncytopathic viral vectors.
|
Academic Article
|
Rabies virus glycoprotein as a carrier for anthrax protective antigen.
|
Academic Article
|
A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice.
|
Academic Article
|
Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease.
|
Academic Article
|
Dominance of a nonpathogenic glycoprotein gene over a pathogenic glycoprotein gene in rabies virus.
|
Academic Article
|
Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity.
|
Academic Article
|
Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene.
|
Academic Article
|
Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity.
|
Academic Article
|
Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates.
|
Academic Article
|
Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge.
|
Academic Article
|
Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics.
|
Grant
|
Functional Analysis of NSV-based HIV vectors
|
Grant
|
A novel rhabdovirus-based anthrax vaccine
|
Grant
|
RABIES VIRUS BASED VECTORS AS AN HIV1 VACCINE
|
Grant
|
Prime/Boost Immunization against HIV-1 by Viral Vectors
|
Grant
|
Rabies Virus-Based Vectors as an HIV-1 Vaccine
|
Grant
|
Rabies Virus-Based Vectors as an HIV -1 Vaccine
|
Grant
|
Development of a single-dose rabies virus vaccine
|
Grant
|
Preclinical characterization of a multivalent killed Filovirus/Rabies vaccine
|
Grant
|
Killed Rhabdoviruses as Novel Anthrax Vaccines
|
Academic Article
|
Inactivated Recombinant Rabies Viruses Displaying Canine Distemper Virus Glycoproteins Induce Protective Immunity against Both Pathogens.
|
Grant
|
Development of Rabies-based Virus-like Particles
|
Grant
|
Training grant on Vaccines and Immunotherapies for Infectious Diseases and Cancer
|
Academic Article
|
Avoiding preventable deaths: The scourge of counterfeit rabies vaccines.
|
Academic Article
|
Rabies-based vaccine induces potent immune responses against Nipah virus.
|
Academic Article
|
Erratum: Publisher Correction: Rabies-based vaccine induces potent immune responses against Nipah virus.
|
Grant
|
Pan-lyssavirus therapeutics and mechanisms of protection against lyssaviruses
|
Grant
|
Multivalent Tick-Microbe targeted Lyme disease vaccines
|
Academic Article
|
Rabies virus-based COVID-19 vaccine CORAVAX™ induces high levels of neutralizing antibodies against SARS-CoV-2.
|
Academic Article
|
Rhabdoviruses as vectors for vaccines and therapeutics.
|
Academic Article
|
Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model.
|
Academic Article
|
A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19.
|
Academic Article
|
SARS-CoV-2 vaccines - the biggest medical research project of the 21st century.
|
Academic Article
|
Measles-based Zika vaccine induces long-term immunity and requires NS1 antibodies to protect the female reproductive tract.
|
Academic Article
|
A Single Dose of the Deactivated Rabies-Virus Vectored COVID-19 Vaccine, CORAVAX, Is Highly Efficacious and Alleviates Lung Inflammation in the Hamster Model.
|
Academic Article
|
Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune response unaffected by vector immunity.
|
Academic Article
|
Effects of adjuvants in a rabies-vectored Ebola virus vaccine on protection from surrogate challenge.
|